| Literature DB >> 34901511 |
Enas Aljuhani1, Meshari M Aljohani2, Amerah Alsoliemy1, Reem Shah1, Hana M Abumelha3, Fawaz A Saad1, Aisha Hossan4, Zehbah A Al-Ahmed5, Ahmed Alharbi1, Nashwa M El-Metwaly1,6.
Abstract
New pyrazole derivatives were prepared and used to synthesize new bioactive agents from Cu(II) complexes that have OSN donors. Analytical and spectral (IR, UV-Vis, MS, 1H NMR, ESR & XRD) instruments characterized these complexes as well as their corresponding ligands. The bonding mode has been modified from ligand to ligand and the molar ratio for isolated complexes has also varied (1:1/1:2, M:L). The geometry of isolated complexes was commonly proposed, based on electronic transitions and ESR spectral-parameters. Via computational approaches, these structures were optimized using standard programs (Gaussian 09 & HyperChem 8.1) under the required basis set. Consequently, important physical characteristics have been obtained after finishing the optimization process. Inhibition behavior of all new synthesizes was studied by MOE module as in-silico approach which conducted versus the crystal structure of NUDT5 protein (6gru) of breast cancer cells. The interaction features summarized from docking processes, reveal effective inhibition validity for new Cu(II) complexes versus breast cancer cells. This according to scoring energy values and the stability of docking complexes in true interaction path (bond length ≤3.5 Å) particularly with Cu(II)-L3 and Cu(II)-L4 complexes. This reflects the possibility of successful behavior during practical application through in-vitro assay that intended in this study. Finally, the degree of toxicity of such new compounds to the breast cancer cell line was determined by in-vitro screening. To judge perfectly on their toxicity, in-vitro screening must compared to positive control as Doxorubicin (reference drug). IC50 values were calculated and represent Cu(II) complexes as outstanding cytotoxic agents which revealed superiority on the reference drug itself.Entities:
Keywords: Anticancer agent; Cu(II) complexes; DFT; EPR; MDE-docking
Year: 2021 PMID: 34901511 PMCID: PMC8639435 DOI: 10.1016/j.heliyon.2021.e08485
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1Synthesis protocol of pyrazinone derivatives.
Figure 2Synthesis outlines for Cu(II)- L3 complexes.
Figure 3The characterization of crystal structure of NUDT5 protein of breast cancer (6gru).
Physical and analytical properties of pyrazole derivatives (L3–5) and their complexes.
| Compounds, (Empirical formula, Mwt. Calcd/Found) | Color | Elemental analysis (%) Calcd (Found) | ||||
|---|---|---|---|---|---|---|
| C | H | N | S | Cu | ||
| 1) L3(C11H11N3OS) (233.29/235.15) | White | 56.63 (56.46) | 4.75 (4.83) | 18.01 (18.14) | 13.74 (13.82) | – |
| 2) [Cu(L3)2](OAc)2 (648.21/649.21) | Brown | 48.18 (48.22) | 4.35 (4.21) | 12.96 (13.10) | 9.89 (9.95) | 9.80 (9.92) |
| 3) L4(C17H15N3OS) (309.39) | Yellow | 66.00 (66.12) | 4.89 (4.78) | 13.58 (13.45) | 10.36 (10.66) | – |
| 4) [Cu(OAc)2 (L4)](H2O) (509.03) | Bluish-green | 49.55 (49.62) | 4.55 (4.65) | 8.25 (8.37) | 6.30 (6.37) | 12.48 (12.51) |
| 5) L5(C12H12N4OS2) (292.05) | Yellow | 49.29 (49.18) | 4.14 (4.33) | 19.16 (19.25) | 21.93 (22.08) | – |
| 6) [Cu(OAc) (L5) (H2O)](OAc) (H2O) (510.04) | Olive-green | 37.68 (37.75) | 4.35 (4.49) | 10.98 (11.14) | 12.57 (12.67) | 12.46 (12.62) |
Essential vibrational bands (cm−1) of pyrazole derivatives (L3–5) and their Cu(II) complexes.
| Compounds | ν(OH); ν(NH) | δ(NH) | ν(C=O) | ν(C=N) | ν(C-S) | δ(OH) | νas, s(OAc) | δr; δw(H2O) | νM-O | νM-S |
|---|---|---|---|---|---|---|---|---|---|---|
| 1) L3 (C11H11N3OS) | ….; 3311 | 1492 | 1643 | 1550 | 689 | – | – | – | – | – |
| 2) [Cu(L3)2](OAc)2 | ….; 3440 | 1497 | 1596 | 1547 | 652 | – | 1454 | – | 557 | 505 |
| 3) L4 (C17H15N3OS) | ….; 3099 | 1492 | 1614 | 1548 | 694 | – | – | – | – | – |
| 4) [Cu(OAc)2 (L4)](H2O) | B.c. at 3415 | 1497 | 1594 | 1543 | 651 | 1390 | 1453,1425 | 865; 620 | 575 | 508 |
| 5) L5 (C12H12N4OS2) | 3318,3204; 3138 | 1593; 1492 | 1654 | 1532 | 698; 809 | – | – | – | – | – |
| 6) [Cu(OAc)(L5)(H2O)](OAc) (H2O) | B.c. at 3235 | 1581; 1516 | 1620 | 1581 | 650; 814 | 1319 | 1463,B at 1389 | 844; 757 | 582 | 503 |
B. c, broad centered.
Electronic transition bands (cm−1), magnetic moments and proposed geometries for Cu(II)-pyrazole complexes.
| Complexes | Λm, Ohm−1 cm2 mol−1 | μeff (BM) | Ligand field bands; assignments | charge transfer bands and intra-ligand transitions | Proposed geometry |
|---|---|---|---|---|---|
| 1) [Cu(L3)2](OAc)2 | 66.91 | 1.74 | 20,833; 2B1g(dz2) → 2Eg(dxz, dyz) | 44,444; 26,316 | Square-planer |
| 2) [Cu(OAc)2(L4)](H2O) | 4.67 | 1.90 | 10,000; 2Eg → 2T2g | 44,843; 24,691 | Distorted octahedral |
| 3) [Cu(OAc)(L5)(H2O)](OAc)(H2O) 36.72 | 1.91 | 13,889; 2Eg → 2T2g | 44,445; 27,027 | Distorted octahedral | |
Figure 4Structural form of Cu(II)-L4 complex.
ESR spectral data for two selected complexes (A and p ×10−4).
| Complex | g// | g⊥ | go | A11 | f | A⊥ | Ao | G | p | k | α2 | β2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1) [Cu(OAc)2(L4)](H2O) | 2.1459 | 2.1022 | 2.1168 | 161.505 | 132.869 | 60.841 | 94.396 | 1.4374 | 285.597 | 0.0062 | 0.6750 | 0.3212 |
| 2) [Cu(OAc)(L5)(H2O)](OAc)(H2O) | 2.1737 | 2.0990 | 2.1239 | 160.831 | 135.154 | 67.724 | 98.760 | 1.7725 | 287.083 | 0.0134 | 0.6996 | 0.5137 |
Figure 5Mass spectrum of Cu(II)-L3 complex.
Figure 6XRD pattern for the best nano-crystalline Cu(II)-L4 complex.
Crystallite parameters using FWHM method for fairly crystalline complexes.
| Compounds | Size (Å) | 2θ | Intensity | d-spacing (Å) | ε | δ (Å−2) | FWHM |
|---|---|---|---|---|---|---|---|
| 1) [Cu(L3)2](OAc)2 | 2.5346 | 6.891 | 40.7 | 12.8173 | 0.6067 | 0.1557 | 0.5724 |
| 2) [Cu(OAc)2(L4)](H2O) | 2.5955 | 21.165 | 52.3 | 4.1945 | 0.1940 | 0.1484 | 0.5676 |
Figure 7HOMO & LUMO images for Cu(II)-L3, Cu(II)-L4 and Cu(II)-L5 complexes.
Figure 8Iso-surface of ESP contour map of Cu(II)-L3, Cu(II)-L4 and Cu(II)-L5 complexes.
Docking parameters for all synthesizes against functional breast cancer protein (6gru).
| Complex | Ligand | Receptor | Interaction | Distance (Å) | E (Kcal/mol) | S (energy score) |
|---|---|---|---|---|---|---|
| 1) L3 | S10 N1 | O GLY 135 (B) N GLU 47 (B) | H-donor H-acceptor | 3.25 3.56 | −1.1–0.7 | −5.258 |
| 2) Cu(II)-L3 | – | – | – | – | – | −6.727 |
| 3) L4 | – | – | – | – | – | −6.500 |
| 4) Cu(II)-L4 | O7 | O GLY 165 (B) | H-donor | 2.94 | −3.1 | −6.604 |
| 5) L5 | O7 S14 S14 | NE2 GLN 82 (A) NE2 GLN 82 (A) N PHE 167 (A) | H-acceptor H-acceptor H-acceptor | 2.98 3.25 3.48 | −1.7 − 1.8 −4.1 | −5.498 |
| 6) Cu(II)-L5 | 6-ring | NH1 ARG 51 (A) | Pi-cation | 3.98 | −0.7 | −6.974 |
Figure 9The docking validity (A) and interaction potential (B) maps of Cu(II)-L3, Cu(II)-L4 and Cu(II)-L5 complexes against 6gru protein.
Cytotoxic data for all complexes against MCF-7 cell line.
| Complexes | In vitro cytotoxicity IC50 (μg/ml) | Toxicity percentage (%) |
|---|---|---|
| Doxorubicin | 26.1 ± 0.2 | 100 |
| 1) Cu(II)-L3 | 25.14 ± 1.7 | 103.82 |
| 2) Cu(II)-L4 | 30.06 ± 2.0 | 86.83 |
| 3) Cu(II)-L5 | 9.12 ± 0.7 | 286.18 |